Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy
Academic Article
Overview
MeSH Major
Angiotensin II Type 1 Receptor Blockers
Antihypertensive Agents
Blood Pressure
Hypertension
Hypertrophy, Left Ventricular
Losartan
abstract
Differences in blood pressure or distribution of add-on medications between treatment groups were not evident in the LIFE trial and, thus, cannot account for the observed outcome difference in the primary endpoint of risk reduction of the composite of cardiovascular death, stroke and MI favoring losartan.
